MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Cash and Cash Equivalents 2011-2026 | BMY
Annual Cash and Cash Equivalents Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 B | 10.3 B | 11.5 B | 9.32 B | 14.3 B | 15 B | 12.3 B | 6.91 B | 5.42 B | 4.24 B | 2.38 B | 5.57 B | 3.59 B | 1.66 B | 5.78 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15 B | 1.66 B | 7.91 B |
Quarterly Cash and Cash Equivalents Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.6 B | 10.9 B | 7.89 B | 6.3 B | 9.33 B | 7.57 B | 8.42 B | 9.05 B | 9.12 B | 7.96 B | 11 B | 12.6 B | 14 B | 13.9 B | 11 B | 11 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 12.3 B | 12.3 B | 12.3 B | 12.3 B | 6.91 B | 6.91 B | 6.91 B | 6.91 B | 5.42 B | 5.42 B | 5.42 B | 5.42 B | 4.24 B | 4.24 B | 4.24 B | 4.24 B | 2.38 B | 2.38 B | 2.38 B | 2.38 B | 5.57 B | 5.57 B | 5.57 B | 5.57 B | 3.59 B | 3.59 B | 3.59 B | 3.59 B | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 5.78 B | 5.78 B | 5.78 B | 5.78 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 B | 1.66 B | 7.36 B |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
65.8 M | $ 2.08 | -14.4 % | $ 214 M |  USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Altimmune
ALT
|
36.9 M | $ 4.2 | -2.67 % | $ 298 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
466 M | $ 20.24 | -3.44 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.8 | 1.87 % | $ 4.36 M |  China |
 |
Aprea Therapeutics
APRE
|
21.6 M | $ 0.88 | -3.72 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
8.71 M | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Aquestive Therapeutics
AQST
|
71.5 M | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
237 M | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
68 M | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
argenx SE
ARGX
|
1.5 B | $ 756.71 | -1.33 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
13.5 M | $ 10.91 | 1.58 % | $ 394 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 25.33 | -6.1 % | $ 3.22 B | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Artelo Biosciences
ARTL
|
600 K | $ 1.15 | -3.36 % | $ 2.32 M | USA |
 |
Arvinas
ARVN
|
143 M | $ 12.97 | -2.3 % | $ 920 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
227 M | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Ascendis Pharma A/S
ASND
|
616 M | $ 231.56 | -0.83 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.39 | -1.63 % | $ 8.16 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
72.9 M | $ 1.17 | -0.85 % | $ 35.2 M | USA |
 |
Atossa Therapeutics
ATOS
|
88.5 M | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Atara Biotherapeutics
ATRA
|
25 M | $ 5.01 | -7.47 % | $ 37.5 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
80.2 M | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.68 | -1.75 % | $ 429 M | Britain |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Atea Pharmaceuticals
AVIR
|
64.7 M | $ 4.69 | 0.21 % | $ 395 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
103 M | $ 4.54 | 2.44 % | $ 387 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
455 M | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
323 M | $ 162.28 | -0.98 % | $ 8.07 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.56 | -0.58 % | $ 16.1 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |